The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms

The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms

Advanced hepatocellular carcinoma (HCC) is a formidable public health problem with limited curable treatment options. Axitinib, an oral tyrosine kinase inhibitor, is a potent and selective second-generation inhibitor of vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3. This anti-angio...

Full description

Bibliographic Details
Main Authors:	Hao Jiang, Jian Liao, Liezhi Wang, Chong Jin, Jinggang Mo, Sheng Xiang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Immunology
Subjects:	axitinib hepatocellular carcinoma survival mechanism tyrosine kinase
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1163967/full

Similar Items

A case of hyperammonemia occurring during treatment of metastatic renal cell carcinoma with axitinib
by: Shoichi Kimura, et al.
Published: (2023-07-01)

Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial
by: Kai-Lin Yang, et al.
Published: (2021-01-01)

Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial
by: Masatoshi Kudo, et al.
Published: (2021-04-01)

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
by: Bellesoeur A, et al.
Published: (2017-09-01)

Development and validation of a nomogram to evaluate the therapeutic effects of second-line axitinib in patients with metastatic renal cell carcinoma
by: Dengqiang Lin, et al.
Published: (2023-02-01)

Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study
by: Alessandra Dicitore, et al.
Published: (2023-11-01)

Hemodiafiltration and plasma levels of axitinib in a patient with metastatic renal clear cell carcinoma
by: Jindrich Kopecky, et al.
Published: (2018-11-01)

Axitinib targets cardiac fibrosis in pressure overload-induced heart failure through VEGFA-KDR pathway
by: Tiantian Jiao, et al.
Published: (2023-11-01)

HPLC method development and validation for the estimation of axitinibe in rabbit plasma
by: Achanta Suneetha, et al.
Published: (2017-10-01)

Photoswitchable Azo- and Diazocine-Functionalized Derivatives of the VEGFR-2 Inhibitor Axitinib
by: Linda Heintze, et al.
Published: (2020-11-01)

Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials
by: Bang-Bin Chen, et al.
Published: (2021-10-01)

Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
by: Chau V, et al.
Published: (2020-08-01)

Sintilimab combined with axitinib in the treatment of advanced chromophobe renal cell carcinoma: a case report
by: Huimin Zhang, et al.
Published: (2024-02-01)

Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases
by: Shinji Tamada, et al.
Published: (2022-11-01)

Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
by: Yuki Katsumata, et al.
Published: (2021-10-01)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
by: Kazuyuki Numakura, et al.
Published: (2021-09-01)

Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib
by: Marie Decraecker, et al.
Published: (2021-12-01)

The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma
by: Shou-Wu Lee, et al.
Published: (2022-08-01)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
by: You-Liang Lai, et al.
Published: (2022-01-01)

Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
by: Masaki Murata, et al.
Published: (2019-04-01)

Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib
by: Koshiro Nishimoto, et al.
Published: (2022-05-01)

Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives
by: Narayan V, et al.
Published: (2016-03-01)

Complete remission of brain metastases in renal cell carcinoma treated with axitinib after failure with nivolumab and ipilimumab treatment
by: Koichiro Takayama, et al.
Published: (2022-11-01)

Case report of a renal cell carcinoma patient with acute pancreatitis under both sunitinib and axitinib treatment
by: Utku Oflazoglu, et al.
Published: (2016-08-01)

Significance of post‐progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma
by: Yoshihiko Yano, et al.
Published: (2022-06-01)

Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
by: Jane L. Roberts, et al.
Published: (2021-09-01)

Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study
by: Guosheng Yuan, et al.
Published: (2024-03-01)

Avelumab plus axitinib therapy for renal cell carcinoma in a patient with pulmonary alveolar proteinosis: A case report
by: Nobuaki Shimizu, et al.
Published: (2021-11-01)

The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
by: Jeffrey Sum-Lung Wong, et al.
Published: (2021-04-01)

Axitinib Rechallenge Restores the Anticancer Effect after Nivolumab: A Case Report
by: Yueh-Shih Chang, et al.
Published: (2023-07-01)

Efficacy and safety of tyrosine kinase inhibitors plus PD-1 inhibitor in patients with transarterial chemoembolization- refractory hepatocellular carcinoma: a two-center retrospective study
by: Ya Gao, et al.
Published: (2023-11-01)

Design, Synthesis, and Biological Evaluation of Axitinib Derivatives
by: Na Wei, et al.
Published: (2018-03-01)

Avelumab plus axitinib for translocation renal cell carcinoma: A case series and literature review
by: Kenta Takahashi, et al.
Published: (2024-03-01)

Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials
by: Lisha Mou, et al.
Published: (2021-10-01)

Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma
by: Ze Zhang, et al.
Published: (2023-02-01)

A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
by: Tiako Meyo M, et al.
Published: (2022-07-01)

Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
by: Yousef Zakharia, et al.
Published: (2022-05-01)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
by: Fei Yang, et al.
Published: (2022-01-01)

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
by: Francesco Tovoli, et al.
Published: (2021-06-01)

A case of an advanced renal collecting duct carcinoma in which initial therapeutic effect was achieved with pembrolizumab plus axitinib
by: Yuichiro Atagi, et al.
Published: (2024-01-01)